GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Return-on-Tangible-Equity

NFL Biosciences (XPAR:ALNFL) Return-on-Tangible-Equity : -327.98% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NFL Biosciences's annualized net income for the quarter that ended in Dec. 2023 was €-3.27 Mil. NFL Biosciences's average shareholder tangible equity for the quarter that ended in Dec. 2023 was €1.00 Mil. Therefore, NFL Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -327.98%.

The historical rank and industry rank for NFL Biosciences's Return-on-Tangible-Equity or its related term are showing as below:

XPAR:ALNFL' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -816.79   Med: -156.89   Max: -61.05
Current: -415.91

During the past 6 years, NFL Biosciences's highest Return-on-Tangible-Equity was -61.05%. The lowest was -816.79%. And the median was -156.89%.

XPAR:ALNFL's Return-on-Tangible-Equity is ranked worse than
93.63% of 1304 companies
in the Biotechnology industry
Industry Median: -46.86 vs XPAR:ALNFL: -415.91

NFL Biosciences Return-on-Tangible-Equity Historical Data

The historical data trend for NFL Biosciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Return-on-Tangible-Equity Chart

NFL Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial -248.15 -156.89 -61.05 -126.22 -816.79

NFL Biosciences Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial - -81.77 -197.13 -338.71 -327.98

Competitive Comparison of NFL Biosciences's Return-on-Tangible-Equity

For the Biotechnology subindustry, NFL Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NFL Biosciences's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's Return-on-Tangible-Equity falls into.



NFL Biosciences Return-on-Tangible-Equity Calculation

NFL Biosciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-3.745/( (0.708+0.209 )/ 2 )
=-3.745/0.4585
=-816.79 %

NFL Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-3.27/( (1.785+0.209)/ 2 )
=-3.27/0.997
=-327.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


NFL Biosciences  (XPAR:ALNFL) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


NFL Biosciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


NFL Biosciences (XPAR:ALNFL) Business Description

Traded in Other Exchanges
Address
199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines